KRP-AM1977X Phase II Clinical Study

KRP-AM1977X Phase II Clinical Study -To assess efficacy, safety and pharmacokinetics of KRP-AM1977X in the patients with community acquired pneumonia-

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222226

Enrollment

120

Registered

2013-09-17

Start date

2013-10-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild to moderate community acquired pneumonia (including Mycoplasma pneumonia, Chlamydia Pneumonia, or Legionella pneumonia)

Interventions

investigational material(s) Generic name etc : KRP-AM1977X INN of investigational material : lascufloxacin Therapeutic category code : 624 Synthetic antibacterials Dosage and Administration for Invest

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Community acquired pneumonia with clear infection symptoms

Exclusion criteria

Exclusion criteria: Pneumonia patient except the community-acquired pneumonia Patient with serious functional disorder that would unsuitable for the study Patient showing the tendency to improve pneumonia symptoms by other agents

Design outcomes

Primary

Measure	Time frame
efficacy Clinical efficacy at test of cure	—

Secondary

Measure	Time frame
efficacy Clinical efficacy at end of treatment	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026